CandlesenseCandlesense
News/Companies/SXTP

SXTP News

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

SXTP

(NASDAQ:SXTP) 60 Degrees Pharma (Nasdaq: SXTP) CEO Dr. Geoff Dow to present at HCW Conference Tuesday, Sept 9, 3:30 PM ET. Live webcast link available.

September 3, 2025Conference
Read more →

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

SXTP

60 Degrees Pharma (Nasdaq: SXTP) Q2 2025: Supply issue cut revenue, profits rose from cash-pay sales; $1.97M cash extends runway to Mar 2026.

August 13, 2025Earnings
Read more →

60 Degrees Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Down -4.81%

SXTP

June 4, 2025
Read more →

Ascendiant Capital Maintains Buy on 60 Degrees, Raises Price Target to $7

SXTP

June 2, 2025
Read more →

60 Degrees Q1 EPS $(1.56) Misses $(1.31) Estimate, Sales $183.01K Miss $227.00K Estimate

SXTP

May 15, 2025
Read more →

60 Degrees Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY FUNGUS BY ADMINISTRATION OF TAFENOQUINE.

SXTP

April 21, 2025
Read more →

Sixty Degrees Pharmaceuticals Announces Patent License Agreement With Yale School Of Medicine And Yale School Of Public Health For The Development And Commercialization Of Tafenoquine In Babesiosis

SXTP

April 8, 2025
Read more →

60 Degrees Pharmaceuticals Says FY 2024 Net Product Revenues Increased 140% To $607,6000 On Growth From Domestic Commercial Sales Of ARAKODA

SXTP

March 28, 2025
Read more →

HC Wainwright & Co. Reiterates Neutral on 60 Degreesto Neutral

SXTP

March 28, 2025
Read more →

HC Wainwright & Co. Reiterates Neutral on 60 Degreesto Neutral

SXTP

February 25, 2025
Read more →

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

SXTP

February 24, 2025
Read more →

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

SXTP

February 22, 2025
Read more →

60 Degrees Pharmaceuticals Announces 1-For-5 Reverse Stock Split; Will Begin Trading On A Split-Adjusted Basis When The Market Opens On February 24, 2025

SXTP

February 20, 2025
Read more →

HC Wainwright & Co. Reiterates Neutral on 60 Degreesto Neutral

SXTP

January 10, 2025
Read more →

HC Wainwright & Co. Reiterates Neutral on 60 Degreesto Neutral

SXTP

December 23, 2024
Read more →

Sixty Degrees Pharmaceuticals And Tufts Medical Center Sign Patent License Agreement To Develop Tafenoquine For Babesiosis Treatment And Prevention; 60 Degrees Gains Exclusive Commercialization Rights With Revenue Sharing And Joint Patent Ownership For Fu

SXTP

December 23, 2024
Read more →

HC Wainwright & Co. Reiterates Neutral on 60 Degrees

SXTP

November 15, 2024
Read more →

60 Degrees Q3 2024 GAAP EPS $(0.93) Misses $(0.70) Estimate, Sales $135.00K Miss $242.00K Estimate

SXTP

November 14, 2024
Read more →